We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App





First Diagnostic Test for Long COVID Provides More Than 90% Accuracy

By LabMedica International staff writers
Posted on 03 Sep 2022

The prevalence of long COVID is thought to be increasing across the UK and Europe, with significant impact both to individuals and to the economy. More...

In April the European Commission said that between 60% and 80% of the EU population was estimated to have been infected with acute COVID-19, while the World Health Organization estimates long COVID affects up to 20% of patients infected with acute COVID. A recent study found that six in 10 patients had at least one persistent COVID-19 symptom, and that patients whose symptoms have not resolved by 15 weeks are likely to experience symptoms for at least a year. Now, the first diagnostic designed to identify patients with long COVID has received CE-IVD marking in Europe and is ready for formal launch in countries accepting the designation in September of this year.

IncellDx (San Carlos, CA, USA) has developed a simple blood test that can help to objectively diagnose patients suffering from Post-Acute Sequelae of COVID-19 (PASC), commonly known as long COVID. The test was developed based on clinical studies published in the peer reviewed journal Frontiers in Immunology, which showed that IncellDx researchers generated credible, objective disease scores for long COVID using machine learning and artificial intelligence to measure and analyze sets of inflammatory markers called cytokines and chemokines. The studies also demonstrated that patients with previous COVID-19 infection and lingering symptoms were found to have a distinct immunologic profile characterized by patterns of inflammatory marker expression. In a subsequent publication, IncellDx found SARS CoV-2 S1 spike protein in monocytic reservoirs of long COVID patients up to 15 months after acute infection.

“Long COVID presents a significant diagnostic and treatment challenge for patients. Many of the symptoms that are associated with long COVID, including fatigue, brain fog, shortness of breath, insomnia, and a wide range of cardiovascular issues, can easily be mistaken for other conditions like post-Lyme, ME-CFS, Fibromyalgia, or even the common cold,” said Bruce Patterson, MD, CEO of IncellDx. “Having an effective - and importantly an objective - tool to diagnose the condition is absolutely essential. An objective test that can detect immune signatures specific to long COVID is vital for effective diagnosis and to enable patients to seek effective treatment.”

“With an estimated 200 million worldwide suffering, and established negative impact to health systems and economies in Europe, the US, India and South America, long COVID is already becoming the world’s next global public health crisis,” Patterson said. “We are pleased that CE marking was granted for the IncellDx incellKINE long COVID test in Europe, and that the test will be made widely available to physicians and their patients soon.”

Related Links:
IncellDx 


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
STI Test
REALQUALITY RQ-SevenSTI
New
Shaking Incubator
Corning LSE 71L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Ear wax could be a possible screening medium for Parkinson’s disease (Photo courtesy of 123RF)

Earwax Test Accurately Detects Parkinson’s by Identifying Odor Molecules

Current tests for Parkinson’s disease (PD) rely heavily on clinical scales and neuroimaging, which are often subjective, expensive, and ill-suited for routine screening. Since most treatments only slow... Read more

Molecular Diagnostics

view channel
Image: Capsule sponge opened to reveal the sponge (Photo courtesy of StillVision)

Capsule Sponge Test Could Replace Endoscopies for Monitoring Esophageal Cancer Risk

Esophageal cancer remains a challenging disease to treat, with fewer than 20% of patients surviving beyond five years of diagnosis—a statistic that has remained largely unchanged for decades.... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The new tool shines a light on elusive genomic patterns (Photo courtesy of Adobe Stock)

Computational Tool Exposes Hidden Cancer DNA Changes Influencing Treatment Resistance

Structural changes in tumor DNA are among the most damaging genetic alterations in cancer, yet they often go undetected, particularly when tissue samples are degraded or of low quality. These hidden genomic... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.